Premium
Clinical Evaluation of PMX‐DHP for Hypercytokinemia Caused by Septic Multiple Organ Failure
Author(s) -
Ikeda Toshiaki,
Ikeda Kazumi,
Nagura Masatoshi,
Taniuchi Hitoshi,
Matsushita Mikiko,
Kiuchi Shintarou,
Kuroki Yuichi,
Suzuki Kaori,
Matsuno Naoto
Publication year - 2004
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1526-0968.2004.00167.x
Subject(s) - medicine , septic shock , shock (circulatory) , hemodynamics , gastroenterology , sepsis , anesthesia , surgery
Endotoxin‐adsorbing fibers have been applied to treat septic shock patients. The limitations of endotoxin hemoadsorption therapy (PMX‐DHP) and the optimal time to start PMX‐DHP were examined in patients with septic multiple organ failure with hypercytokinemia (interleukin‐6 = 1000 pg/mL). Subjects were separated into those who survived more than 28 days after the start of PMX‐DHP therapy (S group) and those who did not (N‐S group). Severity of symptoms and background factors, blood biochemical parameters, hemodynamic parameters, PaO 2 /FiO 2 , pathogens, endotoxin, cytokines, and vascular endothelial cell function‐related markers were examined before and after PMX‐DHP. Number of days from onset of shock (or symptom development) to PMX‐DHP initiation was longer in the N‐S group than in the S group. These results suggest that PMX‐DHP could save more lives in patients with septic multiple organ failure with IL‐6 = 1000 pg/mL when applied early after the onset of shock.